Atualização 1 de 1Mais recenteDia 1
NSW records 1,180 peptide-linked emergency visits amid warnings on online products
Fifteen months of NSW surveillance show a sharp rise in emergency presentations associated with peptide use. The warning concerns unapproved products—not every peptide medicine.
VerFonte mais antigaABC listen
O que sabíamos inicialmente
- 1,180Emergency presentations over fifteen months
- 5Presentations in July 2025
- More than 217Presentations in September 2026
- NSW recorded a sharp rise in emergency presentations associated with peptide use, alongside a ministerial warning about serious harm from unregulated products.
Então ainda em aberto
- The surveillance does not identify the products involved, their verified contents, the number of distinct patients or how many suffered lasting injury.
O que dissemos que iríamos acompanhar
- Product-specific findings, fuller surveillance definitions and patient outcomes would show more clearly what is driving the increase. No date has been announced for the next surveillance release.